Company: HCWB
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0000950170-25-086258
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

As reported in our Current Report on Form 8-K filed on May 15, 2025, HCW Biologics Inc. (the “ Company”) entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. (“ Armistice”) on May 13, 2025 that included a grant of pre-funded warrants to purchase up to 513,140 shares of the Company’s common stock $0.0001 per share (“ Common Stock”) that may be exercised at any time at an exercise price of $0.0001 per share (the “ Pre-Funded Warrants”). As previously reported by the Company, Armistice exercised Pre-Funded Warrants to purchase shares of Common Stock, including 177,140 shares of Common Stock on May 15, 2025, 126,000 shares of Common Stock on May 22, 2025, and 71,000 shares of Common Stock on May 29, 2025. On June 12, 2025, Armistice exercised Pre-Funded Warrants to purchase 85,000 shares of Common Stock and continues to hold Pre-Funded Warrants that may be exercised for 54,000 shares of Common Stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                         HCW BIOLOGICS INC.                   
  Date:      June 13, 2025      By:      /s/ Hing C. Wong                     
                                         Founder and Chief Executive Officer